Scientists turn E. coli bacteria into a mercury sensor
According to the authors, these new platforms are possible today thanks to advances in synthetic biology and bioelectrochemistry.
Traditional biosensors, such as those based on enzymes, are often fragile, costly and/or have a slow response time in complex environments. Whole-cell biosensors, which use living microorganisms, can maintain and repair themselves and operate inside contaminated samples. However, in most conventional designs, these biosensors' output signals are in the optical range, which is harder to integrate into portable or field-deployable electronics.
In their study, the researchers built a modular biosensor that could sense the presence of specific compounds and convert that into an electrical signal, which is compatible with low-cost electronics.
The team used genetically engineered Escherichia coli bacteria as 'containers'. The microbes hosted three biosensor modules. The sensing module detected a target chemical through specific molecular regulators. The information processing module amplified or processed the signal. And the output module produced phenazines, nitrogen-containing organic molecules that can be measured using an electrochemical technique called voltammetry.
This way, the researchers built two biosensors. The first one could detect arabinose, a simple plant sugar often used in lab media. When a sample containing the sugar came in contact with the bacteria, the cells started producing phenazine-1-carboxylic acid. When this molecule touched the electrode, the latter produced a current that rose with sugar level. The signal appeared in roughly two hours.
The second sensor detected mercury ions in water. Because these ions are present only in trace quantities in real-world water, the researchers added a genetic amplifier to the E. coli. When the mercury bound with a protein called MerR, the meeting triggered the production of a polymerase that pushed the phenazine production pathway into overdrive. As a result, just 25 nanomoles of mercury — below the WHO safety limit — produced a readable current within three hours.
The team also demonstrated an 'AND' logic gate inside E. coli, so that it produced a signal only when two specific molecules were present together.
The team thus established a proof of concept of a living, electronically integrated biosensor capable of detecting compounds in its surroundings, processing the signals, and supplying data.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 days ago
- The Hindu
How technology can help ease dementia diagnosis and care burden in India
Dementia is a growing problem, particularly in a country like India, which has a rapidly ageing population. Awareness, diagnosis and access to care however, continue to remain limited. Can digital and assistive technologies help? Researchers and doctors say there is a lot of potential, but the challenge is, in making them affordable for patients. The burden According to the World Health Organization (WHO), over 55 million people worldwide live with dementia, with nearly 10 million new cases added annually. Alzheimer's disease is the most common form, contributing to 60–70% of cases. Low- and middle-income countries, including India, bear the greatest burden, with dementia prevalence expected to triple by 2050 due to demographic ageing. Emerging technologies 'In India, assistive and digital technologies are emerging as force multipliers,' said Prabash Prabhakaran, director and senior consultant, neurology, SIMS Hospital, Chennai. These range from GPS trackers and low-cost Internet of Things (IoT) wearables for patients who wander or leave their designated areas, to home sensors that monitor movement, appliance usage, or medication adherence. Smartwatches and wearable devices for activity, sleep and fall detection are becoming more common, while smartphone-based cognitive screening apps and gamified brain-training tools are in validation stages. Virtual reality modules are also being piloted, designed in vernacular languages and Indian cultural settings for reminiscence therapy and navigation training. At the research frontier, Indian centres are developing blood-based biomarker panels for early Alzheimer's detection, alongside AI-driven multimodal digital biomarkers that combine gait, speech, typing patterns and passive smartphone signals. 'Earlier and scalable detection is becoming possible because smartphone penetration is high, even among older households,' Dr. Prabhakaran explained. Studies have shown that keystroke dynamics, speech analysis and passive phone use can serve as unobtrusive early-warning signals. Sindhuja L., consultant neurophysician at V.S. Hospitals, Chennai, said AI now picks up subtle changes 'in brain scans, speech or even handwriting that escape the human eye.' She noted that digital biomarkers such as walking speed and reaction time are being captured on tablets and smartphones, even by mobile health units visiting rural communities. Dr. Prabhakaran stressed that these technologies are not replacements for clinical diagnosis, but 'powerful early detection and monitoring tools, especially valuable in India where clinic-based testing is episodic.' Easing caregiver stress 'Dementia disrupts daily living, independence, and safety while burdening caregivers. Assistive technologies help maintain independence and reduce stress,' Dr. Prabhakaran said. In practice, families are using GPS trackers, pill-box alarms, fall detectors, and voice-assisted reminders. Smart-home solutions, such as motion-triggered lights and automatic stove shut-offs, are now feasible in urban settings. Therapeutic tools also show promise. Virtual reality reminiscence therapy has allowed patients to revisit festivals or familiar neighbourhoods, sparking positive memories. 'When families join in brain-training games in local languages, they turn into a shared, engaging activity instead of a medical routine,' Dr. Sindhuja said. Gaps and digital-first solutions Nearly two-thirds of India's older adults live in rural areas, where dementia specialists are scarce. 'Travel distance, cost, stigma, and shortage of trained specialists mean many cases remain undiagnosed or untreated,' Dr. Prabhakaran said. Here, telemedicine, remote monitoring, and community-driven digital platforms offer a bridge. Accredited frontline health workers can use smartphone screening apps, while caregivers rely on WhatsApp-based peer groups for emotional and practical support. Dr. Sindhuja emphasised that 'scheduled video calls or remote monitoring can catch problems before they escalate, making care less isolating.' High costs, lack of insurance, and uneven after-sales support remain critical hurdles. 'Most advanced devices are imported and unaffordable for average families,' said Dr. Sindhuja. In rural areas, poor connectivity worsens access. Cultural barriers also persist, as memory loss is still seen as part of normal ageing, leading to delayed care-seeking. Considering these challenges, Sridhar Vaitheeswaran, consultant psychiatrist and the head of DEMCARES (Dementia Care in SCARF) at the Schizophrenia Research Foundation (SCARF) in Chennai, said the Foundation, in collaboration with Imperial College London, has been working on technologies like the humanoid robot to assist people living with dementia, offering companionship and cognitive support. SCARF is also developing virtual reality services and using platforms such as Zoom to help patients connect with their families. The aim is to improve these tools and create more seamless ways for people with dementia to stay engaged and supported. Need for subsidies Dr. Prabhakaran called for policy interventions including subsidies, insurance inclusion, and local-language adaptation. He proposed 'digital dementia corners' at primary health centres, equipped with tablets, VR stations, and screening kiosks. Doctors emphasised the need for public–private partnerships to localise production, ensure affordability, and drive awareness campaigns in regional languages. Towards a national dementia-tech ecosystem A wide range of assistive technologies is used globally-- In Japan, scannable QR codes and wearable barcodes are widely used to help locate individuals who wander. The U.K. promotes the use of reminder clocks, smart home sensors and medication dispensers through the National Health Services and dementia charities. In the U.S., devices like AngelSense integrate GPS tracking, two-way communication and fall detection, offering comprehensive monitoring. Australia supports telecare systems and simplified tablets for memory and social engagement. Sweden and the Netherlands are pioneers in using smart homes and robotic companions for dementia care, incorporating AI and ambient monitoring. These innovations, however, remain out of reach for most Indian families. The challenge, experts argue, is not just scientific but systemic, ensuring that validated, affordable, culturally relevant technologies reach homes across India. The path forward lies in scalable, inclusive technology, integrated with grassroots healthcare and caregiver networks. As Dr. Prabhakaran explained, 'Assistive devices, GPS trackers, smart-home solutions, and therapeutic tools are not luxuries: they are critical enablers of safer, more independent living. With proper validation, affordability, and integration into national elder-care programmes, these technologies can transform dementia care in the coming decade.'
The Hindu
4 days ago
- The Hindu
Scientists turn E. coli bacteria into a mercury sensor
In a step towards building cheap and programmable bioelectronic devices, Imperial College London and Zhejiang University researchers have shown in a new study that genetically engineered bacteria can be turned into self-powered chemical sensors that interface directly with electronics. According to the authors, these new platforms are possible today thanks to advances in synthetic biology and bioelectrochemistry. Traditional biosensors, such as those based on enzymes, are often fragile, costly and/or have a slow response time in complex environments. Whole-cell biosensors, which use living microorganisms, can maintain and repair themselves and operate inside contaminated samples. However, in most conventional designs, these biosensors' output signals are in the optical range, which is harder to integrate into portable or field-deployable electronics. In their study, the researchers built a modular biosensor that could sense the presence of specific compounds and convert that into an electrical signal, which is compatible with low-cost electronics. The team used genetically engineered Escherichia coli bacteria as 'containers'. The microbes hosted three biosensor modules. The sensing module detected a target chemical through specific molecular regulators. The information processing module amplified or processed the signal. And the output module produced phenazines, nitrogen-containing organic molecules that can be measured using an electrochemical technique called voltammetry. This way, the researchers built two biosensors. The first one could detect arabinose, a simple plant sugar often used in lab media. When a sample containing the sugar came in contact with the bacteria, the cells started producing phenazine-1-carboxylic acid. When this molecule touched the electrode, the latter produced a current that rose with sugar level. The signal appeared in roughly two hours. The second sensor detected mercury ions in water. Because these ions are present only in trace quantities in real-world water, the researchers added a genetic amplifier to the E. coli. When the mercury bound with a protein called MerR, the meeting triggered the production of a polymerase that pushed the phenazine production pathway into overdrive. As a result, just 25 nanomoles of mercury — below the WHO safety limit — produced a readable current within three hours. The team also demonstrated an 'AND' logic gate inside E. coli, so that it produced a signal only when two specific molecules were present together. The team thus established a proof of concept of a living, electronically integrated biosensor capable of detecting compounds in its surroundings, processing the signals, and supplying data.
Hans India
4 days ago
- Hans India
Probiotics for preterm babies may lower antibiotic-resistant bacteria in gut: Study
Preterm babies with very low birth weight who received a probiotic alongside antibiotics had fewer multidrug-resistant bacteria and a more typical gut microbiome, according to a study. The study, published in the journal Nature Communications, is based on a trial testing probiotics among a group of 34 preterm babies born with a very low birth weight, under 1,500g, representing around 1-1.5 per cent of babies born around the world. Researchers from the University of Birmingham in the UK sequenced gut bacteria from the babies during the first three weeks after birth. They found that among babies who received a probiotic treatment of a certain strain, including Bifidobacterium, alongside antibiotics -- the typical bacterial strains associated with early-life gut microbiota -- were at levels typical among full-term babies. This helped reduce both the abundance of antibiotic resistance genes and the number of multidrug-resistant bacteria in the gut. There were also lower levels of drug-resistant pathogens, including Enterococcus, associated with risks of infections and longer hospital stays. "We have already shown that probiotics are highly effective in protecting vulnerable preterm babies from serious infections, and this study now reveals that these probiotics also significantly reduce the presence of antibiotic resistance genes and multidrug-resistant bacteria in the infant gut,' said Professor Lindsay Hall from the University of Birmingham. Babies who received probiotics also saw higher levels of certain positive bacteria found naturally in the gut. Among babies who didn't receive probiotics, analysis of the gut bacteria found that while some differences occurred between those receiving antibiotics or not, both groups saw a dominant microbiome develop that included key bacteria (pathobionts) that can cause health problems, including life-threatening infections during the crucial period after birth, as well as in later life. "In the context of the global AMR crisis, this is a major finding, especially for NICUs where preterm infants are especially vulnerable. Probiotics are now used in many neonatal ICUs around the UK, and the WHO has recommended probiotic supplementation in preterm babies,' Hall said. "Our paper shows how beneficial this intervention can be for babies born prematurely to help them give their gut a kickstart, and reduce the impact of concerning pathogens taking hold," she added. The study showed that probiotic Bifidobacterium rapidly replicates in the preterm gut during the first three weeks of life, driving the maturation of the gut microbiota. It is also linked to a noticeable reduction in multidrug-resistant pathogens -- pointing to its pivotal role in improving neonatal health.
